Literature DB >> 14586540

The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

Eduardo R Butelman1, Todd J Harris, Mary Jeanne Kreek.   

Abstract

RATIONALE: Salvinorin A is the active component of the hallucinogenic plant Salvia divinorum. The potential mode of action of this hallucinogen was unknown until recently. A recent in vitro study detected high affinity and efficacy of salvinorin A at kappa-opioid receptors. It was postulated that salvinorin A would produce discriminative stimulus effects similar to those of a high efficacy kappa-agonist (U69,593) in rhesus monkeys.
METHODS: Monkeys were previously trained to discriminate U69,593 (0.0056 or 0.013 mg/kg; s.c.) from vehicle in a food-reinforced FR20 (fixed ratio 20) operant conditioning procedure (n=3). The ability of salvinorin A to cause generalization (> or =90% U69,593-appropriate responding) was examined in time course and cumulative dose-effect curve studies.
RESULTS: All subjects dose-dependently emitted full U69,593-appropriate responding after salvinorin A (0.001-0.032 mg/kg, SC). Salvinorin A-induced generalization started 5-15 min after injection, and dissipated by 120 min. The opioid antagonist quadazocine (0.32 mg/kg) fully blocked the effects of salvinorin A. The kappa-selective antagonist GNTI (1 mg/kg; 24 h pretreatment) did not cause significant antagonism of the effects of salvinorin A (GNTI, under these conditions, was only effective as an antagonist in two of three monkeys). The NMDA antagonist ketamine (0.1-3.2 mg/kg) was not generalized by any subject, indicating that not all compounds that produce hallucinogenic or psychotomimetic effects in humans are generalized by subjects trained to discriminate U69,593.
CONCLUSIONS: The naturally occurring hallucinogen salvinorin A produces discriminative stimulus effects similar to those of a high efficacy kappa-agonist in non-human primates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586540     DOI: 10.1007/s00213-003-1638-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Effects of systemically administered dynorphin A(1-17) in rhesus monkeys.

Authors:  E R Butelman; T J Harris; A Perez; M J Kreek
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

2.  Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.

Authors:  S L Walsh; E C Strain; M E Abreu; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2001-09       Impact factor: 4.530

3.  Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.).

Authors:  L J Valdés; J L Díaz; A G Paul
Journal:  J Ethnopharmacol       Date:  1983-05       Impact factor: 4.360

4.  Analgesic effects of phencyclidine-like drugs in rhesus monkeys.

Authors:  C P France; A M Snyder; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

5.  Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys.

Authors:  Eduardo R Butelman; Jonathan W Ball; Mary-Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2002-08-08       Impact factor: 4.530

6.  Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.

Authors:  S Stevens Negus; Nancy K Mello; David C Linsenmayer; R M Jones; Philip S Portoghese
Journal:  Psychopharmacology (Berl)       Date:  2002-03-13       Impact factor: 4.530

7.  Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.

Authors:  T A Bowdle; A D Radant; D S Cowley; E D Kharasch; R J Strassman; P P Roy-Byrne
Journal:  Anesthesiology       Date:  1998-01       Impact factor: 7.892

8.  Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland.

Authors:  C Giroud; F Felber; M Augsburger; B Horisberger; L Rivier; P Mangin
Journal:  Forensic Sci Int       Date:  2000-08-14       Impact factor: 2.395

9.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

Review 10.  Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A.

Authors:  L J Valdés
Journal:  J Psychoactive Drugs       Date:  1994 Jul-Sep
View more
  31 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 3.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

4.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

5.  Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.

Authors:  Daniela Braida; Valeria Limonta; Simona Pegorini; Alessia Zani; Chiara Guerini-Rocco; Enzo Gori; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

7.  LC-MS/MS quantification of salvinorin A from biological fluids.

Authors:  Michael J Caspers; Todd D Williams; Kimberly M Lovell; Anthony Lozama; Eduardo R Butelman; Mary Jeanne Kreek; Matthew Johnson; Roland Griffiths; Katherine Maclean; Thomas E Prisinzano
Journal:  Anal Methods       Date:  2013-12-21       Impact factor: 2.896

8.  Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Authors:  Cécile Béguin; Katharine K Duncan; Thomas A Munro; Douglas M Ho; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem       Date:  2008-12-14       Impact factor: 3.641

9.  The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.

Authors:  Eduardo R Butelman; Szymon Rus; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2010-01-19       Impact factor: 4.530

10.  Herkinorin analogues with differential beta-arrestin-2 interactions.

Authors:  Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2008-04-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.